Cel-Sci (CVM) Stock: Buy, Sell, or Hold?
CVM - Cel-Sci Corporation
$2.74
0.32 (13.22%)
▲
5d:
+53.07%
30d:
+68.1%
90d:
+94.33%
WAIT
LOW Confidence
Analysis Updated: Oct 6, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CVM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: CVM is 37.0% above its trading range ($2.00). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: CVM is 37.0% above its trading range ($2.00). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: CVM is currently trading at $2.74, which is considered extended relative to its 30-day fair value range of $1.46 to $2.00.
Technical Outlook: Technically, CVM is in a strong uptrend. Immediate support is located at $1.67, while resistance sits at $2.83. The stock is showing strong short-term momentum, up 13.2% recently.
Market Sentiment: CVM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.50 (+356.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CVM is in a strong uptrend. Immediate support is located at $1.67, while resistance sits at $2.83. The stock is showing strong short-term momentum, up 13.2% recently.
Market Sentiment: CVM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.50 (+356.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.46 -
$2.00
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+37.0% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+13.2%)
- BULLISH: Trading 356.2% below Wall St target ($12.50)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.46 -
$2.00
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.67
Resistance Level
$2.83
Current Trend
Strong Uptrend
Technical data as of
Oct 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.43
Wall Street Target
$12.50
(+356.2%)
Revenue Growth (YoY)
-62.7%
Share & Embed Analysis
Last updated: October 06, 2026 11:33 PM ET
Data refreshes hourly during market hours. Next update: 12:33 AM
Data refreshes hourly during market hours. Next update: 12:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CVM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$294 | 63 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
27 analysts |
$853 | 58 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
19 analysts |
$644 | 64 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$32 | 57 HOLD |
